Lannett Company, Inc.
LCI · New York Stock Exchange · USD
0,6855USD
0,00 (0,00 %)Stand 19. Apr., 19:58
Kennzahlen
- Eröffnung
- 0,65
- Vortag
- 0,66
- Tagesspanne
- 0,6501 – 0,7196
- 52 Wochen
- 0,0111 – 3,72
- Volumen
- 280.660
- Ø Volumen
- 208.268
- Börsenwert
- 7,38 Mio. $
- KGV
- -0,0
- Gewinn je Aktie (TTM)
- -25,30
- Dividendenrendite
- 0,0 %
- Beta
- 0,9
- Nächste Zahlen
- –
Finanzen
| USD | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|
| Umsatz | 340,58 Mio. | 478,78 Mio. | 545,74 Mio. | 655,41 Mio. | 684,56 Mio. |
| Herstellungskosten | 307,41 Mio. | 403,19 Mio. | 380,52 Mio. | 411,8 Mio. | 395,86 Mio. |
| Bruttogewinn | 33,17 Mio. | 75,59 Mio. | 165,22 Mio. | 243,61 Mio. | 288,71 Mio. |
| Forschung und Entwicklung | 22,36 Mio. | 24,17 Mio. | 29,98 Mio. | 38,81 Mio. | 29,2 Mio. |
| Vertrieb und Verwaltung | 81,02 Mio. | 68,08 Mio. | 79,47 Mio. | 87,65 Mio. | 82,2 Mio. |
| Operatives Ergebnis | −70,22 Mio. | −16,66 Mio. | −1,37 Mio. | 59,54 Mio. | 129,7 Mio. |
| EBITDA | −83,7 Mio. | 19,4 Mio. | 53,6 Mio. | 115,84 Mio. | 191,84 Mio. |
| Nettogewinn | −231,62 Mio. | −363,48 Mio. | −33,37 Mio. | −272,11 Mio. | 28,69 Mio. |
| Gewinn je Aktie (verwässert) | -22,96 | -2,29 | -0,21 | -1,76 | 0,19 |
Umsatz nach Segment
Produkte · FY 2022
- Central Nervous System78,33 Mio. $23,00 %−17,65 %
- Gastrointestinal51,03 Mio. $14,98 %−24,45 %
- Cardiovascular45,38 Mio. $13,32 %−31,23 %
- Other41,29 Mio. $12,12 %
- Infectious Disease28,01 Mio. $8,22 %−58,67 %
- Endocrinology27,49 Mio. $8,07 %+1,56 %
- Migraine16,32 Mio. $4,79 %
- Analgesic15,74 Mio. $4,62 %+7,17 %
- Anti-Psychosis11,79 Mio. $3,46 %
- Contract manufacturing revenue11,67 Mio. $3,43 %
- Respiratory/Allergy/Cough/Cold8,96 Mio. $2,63 %
- Urinary4,59 Mio. $1,35 %−20,71 %
Anteil · ggü. Vorjahr (FY 2021)
Bewertung
Letzte 12 Monate
- KGV
- -0,0
- Kurs-Umsatz-Verhältnis
- 0,0
- Kurs-Buchwert-Verhältnis
- -0,0
- PEG
- 0,0
- Bruttomarge
- 9,7 %
- Operative Marge
- −20,6 %
- Nettomarge
- −68,0 %
- Verschuldungsgrad
- -2,5
- EV/EBITDA
- -6,5
- Eigenkapitalrendite
- 166,3 %
- Kapitalrendite (ROIC)
- −18,2 %
- Free-Cashflow-Rendite
- −238,7 %
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | |
|---|---|---|---|---|---|
| Bruttomarge | 9,7 % | 15,8 % | 30,3 % | 37,2 % | 42,2 % |
| Operative Marge | −20,6 % | −3,5 % | −0,3 % | 9,1 % | 18,9 % |
| Nettomarge | −68,0 % | −75,9 % | −6,1 % | −41,5 % | 4,2 % |
| KGV | -0,1 | -8,2 | -138,3 | -13,4 | 286,3 |
| Kurs-Umsatz-Verhältnis | 0,1 | 6,2 | 8,3 | 5,6 | 12,1 |
| Kurs-Buchwert-Verhältnis | -0,1 | -108,1 | 14,9 | 11,0 | 13,9 |
| Verschuldungsgrad | -2,5 | -22,0 | 2,3 | 2,2 | 1,4 |
| Liquidität 3. Grades | 2,8 | 3,9 | 2,1 | 2,7 | 2,6 |
| Dividendenrendite | 0,0 % | 12,0 % | 1,9 % | 0,0 % | 1,1 % |
| Unternehmenswert | 562,56 Mio. | 3,48 Mrd. | 5,07 Mrd. | 4,26 Mrd. | 9,04 Mrd. |
| EV/EBITDA | -6,7 | 179,4 | 94,6 | 36,7 | 47,1 |
| Eigenkapitalrendite | 92,3 % | 1.323,1 % | −11,0 % | −81,5 % | 4,8 % |
| Kapitalrendite (ROIC) | −18,2 % | −2,8 % | −0,1 % | 4,3 % | 5,1 % |
| Free-Cashflow-Rendite | −75,3 % | 1,5 % | 1,5 % | 4,1 % | 0,6 % |
Wachstum
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | |
|---|---|---|---|---|---|
| Umsatz | −28,9 % | −12,3 % | −16,7 % | −4,3 % | +7,4 % |
| Bruttogewinn | −56,1 % | −54,2 % | −32,2 % | −15,6 % | −5,4 % |
| Operatives Ergebnis | −321,5 % | −1.112,4 % | −102,3 % | −54,1 % | +50,0 % |
| Nettogewinn | +36,3 % | −989,4 % | +87,7 % | −1.048,4 % | +5.038,0 % |
| Gewinn je Aktie | −902,6 % | −990,5 % | +88,1 % | −1.026,3 % | +4.971,8 % |
| Freier Cashflow | −138,3 % | −33,3 % | −53,8 % | +215,8 % | −59,6 % |
| Dividende je Aktie | −100,0 % | +304,4 % | 0,0 % | −100,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 0Stark kaufen
- 1Kaufen
- 0Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
Gerade nicht verfügbar.
Quartalszahlen
| Feb. 2023 | Nov. 2022 | Aug. 2022 | Mai 2022 | Feb. 2022 | Nov. 2021 | Aug. 2021 | Mai 2021 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | -1,64 | -1,84 | -1,84 | -1,72 | -1,28 | -1,00 | -0,32 | -0,20 |
| Gewinn je Aktie · Tatsächlich | -1,36 | -1,68 | -1,76 | -1,64 | -1,56 | -1,08 | -0,76 | 0,08 |
| Abweichung | +17,07 % | +8,70 % | +4,35 % | +4,65 % | −21,88 % | −8,00 % | −137,50 % | +140,00 % |
| Umsatz · Tatsächlich | 80,89 Mio. | 75,08 Mio. | 74,19 Mio. | 78,36 Mio. | 86,51 Mio. | 101,53 Mio. | 106,01 Mio. | 112,37 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
- 7. Feb. 20231:4
- 3. März 20033:2
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
- Chapman John C17. Nov. 2022 · directorKauf20.000 Aktien · 0,51
- LEPORE PATRICK G10. Nov. 2022 · directorKauf100.000 Aktien · 0,49
- Crew Timothy C10. Nov. 2022 · officer: Chief Executive OfficerKauf15.000 Aktien · 0,48
- Rewolinski Melissa14. Sept. 2022 · directorKauf31.159 Aktien · 0,49
- KOZLOWSKI JOHN7. Sept. 2022 · officer: VP of Finance & CFOVerkauf775 Aktien · 0,47
- Abt John7. Sept. 2022 · officer: Chief Quality and OperationsVerkauf950 Aktien · 0,47
- Abt John29. Juli 2022 · officer: Chief Quality and OperationsVerkauf3924 Aktien · 0,58
- Cavanaugh Maureen29. Juli 2022 · officer: Senior Vice President and CCOOVerkauf5656 Aktien · 0,58
Vergleichbare Unternehmen
DMKPQDMK Pharmaceuticals Corporation0,00010,00 %
FRTXFresh Tracks Therapeutics, Inc.0,935−0,53 %
HLTHQCue Health Inc.0,00010,00 %
KAKineta, Inc.0,5746−30,77 %
MODVModivCare Inc.0,43190,00 %
NLTXNeoleukin Therapeutics, Inc.3,49+1,45 %
OMGAOmega Therapeutics, Inc.0,14260,00 %
STRRStar Equity Holdings, Inc.9,15+4,10 %
Über das Unternehmen
Lannett Company, Inc. operates as a U.S.-based pharmaceutical firm dedicated to the comprehensive process of developing, manufacturing, packaging, commercializing, and distributing generic versions of established brand-name drugs. Its extensive product portfolio encompasses a wide array of dosage forms, including solid oral, extended-release, topical, liquid, nasal, ophthalmic, injectable, patch, foam, buccal, sublingual, and suspension preparations. These generic medications address a broad spectrum of therapeutic areas, such as cardiovascular health, central nervous system disorders, endocrinology, gastrointestinal issues, infectious diseases, pain management, respiratory conditions, and mental health. Notable among its offerings are generic versions of critical medications such as Levothyroxine Sodium, Fluphenazine, Posaconazole, Verapamil SR, Methylphenidate, Omeprazole, and Sumatriptan Nasal spray, alongside others like Amphetamine IR tablets and cocaine hydrochloride solution. Lannett serves a broad and diverse client base, encompassing generic pharmaceutical distributors, drug wholesalers, major chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, and governmental entities. The company actively engages in strategic partnerships, maintaining supply and development agreements with key collaborators such as Summit Bioscience LLC, HEC Group, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and numerous other entities. Founded in 1942, Lannett Company, Inc. maintains its headquarters in Trevose, Pennsylvania.
Führung
- Timothy C. CrewChief Executive Officer & Director
- Maureen CavanaughSenior Vice President & Chief Commercial Operations Officer
- John KozlowskiVice President of Fin., Chief Financial Officer & Principal Accounting Officer
- Samuel H. IsraelGen. Counsel & Chief Legal Officer
- John AbtVice President and Chief Quality, Information Technology & Operations Officer
- Kristie StephensChief Compliance Officer & Vice President of Regulatory Affairs
- CEO
- Timothy C. Crew
- Mitarbeitende
- 564
- Hauptsitz
- Trevose, PA, US
- Sektor
- Healthcare
- Branche
- Drug Manufacturers - Specialty & Generic
- Börsengang
- 13. Dez. 2013
- Website
- lannett.com
Nachrichten
- Business Wire · 10. Nov., 7:30LCI Board Determines that Revised, Unsolicited, Non-Binding Proposal from Monomoy Capital Partners Does Not Constitute a Superior Proposal
- MarketBeat · 7. Nov., 21:14LCI Industries Q3 Earnings Call Highlights
- Business Wire · 5. Nov., 7:00LCI Industries Reports Third Quarter Financial Results
- Business Wire · 30. Okt., 7:30LCI Board Determines That the Unsolicited, Non-Binding Proposal From Monomoy Capital Partners Does Not Constitute a Superior Proposal
- PRNewsWire · 28. Okt., 6:03Patrick Industries, Inc. Reaffirms Merger Agreement with LCI Industries
- Business Wire · 28. Okt., 6:00LCI Industries Confirms Receipt of Unsolicited, Non-Binding Proposal from Monomoy Capital Partners
- Business Wire · 22. Okt., 13:23LCI Industries Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LCI Industries - LCII
- Business Wire · 22. Okt., 8:00LCI Industries Third Quarter 2026 Conference Call Scheduled for November 5, 2026, at 8:30 a.m. ET
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.